Takeda gets China NMPA nod for Livtencity to treat certain CMV patients
The authorisation was based on the findings from the Phase 3 SOLSTICE trial in which Livtencity was found…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Dec 23
The authorisation was based on the findings from the Phase 3 SOLSTICE trial in which Livtencity was found…
21 Dec 23
OCE-205 is a therapeutic peptide with a differentiated mechanism of action, designed to relieve portal hypertension while offering…
21 Dec 23
Palatin's focus is solely on its development and clinical pipeline based on the melanocortin receptor system
21 Dec 23
Currently, there is no other FDA-cleared software indicated for the analysis of neuromelanin MRI on the market, making…
20 Dec 23
Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions
20 Dec 23
Neurogene focused on advancing Phase 1/2 trial for NGN-401, a differentiated clinical stage gene therapy to treat Rett…
19 Dec 23
Manufactured from pooled human plasma from American donors, Alyglo is a liquid solution with 10% immunoglobulin G (100…
19 Dec 23
Most of these products have been developed by Biocon Biologics and are being manufactured at its world-class facilities…
18 Dec 23
The recommendation will be considered by the European Commission in deciding whether to allow Hyqvia for CIDP to…
18 Dec 23
CymaBay seeks approval for PBC management including pruritus in adults without cirrhosis or with compensated cirrhosis who are…